6-ketoprostaglandin-f1-alpha and puerarin

To investigate the effects and possible mechanisms of puerarin on the vascular active factors correlated to cerebral vasospasm (CVS) after aneurysm subarachnoid hemorrhage (aSAH).. Fifty-four patients with aSAH were randomly assigned to the puerarin group (30 cases) and the control group (24 cases) by lot. On the basis of routine treatment, the patients in the puerarin group were intravenously dripped with 0.5 g puerarin by adding in 250 mL glucose injection once daily. The injection was given starting from the 3rd day of the disease course, for 14 successive days. The plasma levels of nitric oxide (NO), endothelin-1 (ET-1), thromboxane B, (TXB2), 6-Keto-prostaglandin F1alpha (6-K-PGF1alpha) were compared between the two groups pre- and post-therapy. The incidence of cerebral vasospasm (CVS) was observed using transcranial Doppler (TCD). The Glasgow outcome scale (GOS) were compared at discharge between the two groups.. Compared with the control group, the plasma levels of NO, ET-1, and 6-K-PGF1alpha increased in the puerarin group (P < 0. 05), the TXB2 level decreased (P < 0.05), the incidence of CVS decreased (P < 0.05), the mean MCA velocity increased (P < 0.05), and the GOS at discharge increased (P < 0.05).. Puerarin is an effective agent for the prophylaxis and treatment of the CVS in patients after aSAH. Moreover, it can improve the prognosis. The mechanism might be correlated with improving the levels of the vascular active factors, i.e., increasing the plasma levels of NO and PGl2, decreasing TXA, in plasma, increasing the cerebral blood flow, and improving cerebral perfusion.

Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Endothelin-1; Female; Humans; Isoflavones; Male; Middle Aged; Nitric Oxide; Prognosis; Subarachnoid Hemorrhage; Thromboxane B2; Vasospasm, Intracranial

Plasma concentrations of thromboxane B2 (TXB2) and 6-keto-prostaglandin Fl alpha(6-K-PGFl alpha), the stable nonenzymatic metabolites of TXA2 and prostacyclin were assayed in 30 patients suffering from angina pectoris before and after administration of puerarin. In addition, serum lipids and HDL were also measured at the same time. 20 healthy subjects were chosen as the control group. Two weeks before and during administration of puerarin, aspirin, calcium-antagonists, all kinds of hypotensors and drugs relieving chest pain of angina pectoris were strictly prohibited. Puerarin was intravenously given, 500 mg daily for 7 days, which was considered as a therapeutic course. Besides relieving of chest pain, decreasing of heart rate and reduction of blood pressure clinically, it was also found that plasma 6-K-PGFl alpha concentrations were significantly elevated from 38.32 +/- 15.40 to 158. 79 +/- 98.62 pg (P less than 0.01) after administration of puerarin, but there was no significantly difference between plasma TXB2 concentrations before and after administering the drug. In addition, serum HDL was apparently enhanced as compared with that before the administration of puerarin (P less than 0.01). The results indicated that puerarin has the function of anti-angina, reducing both systolic and diastolic blood pressure and diminishing myocardial oxygen consumption.

Topics: 6-Ketoprostaglandin F1 alpha; Adult; Angina Pectoris; Female; Flavonoids; Humans; Isoflavones; Male; Oxygen Consumption; Radioimmunoassay; Thromboxane B2; Vasodilator Agents